Indian Courts Examine Cancer Drug Pricing and Affordability Disputes
The Supreme Court of India has questioned the large price gap between the maximum retail price (MRP) and retail price of certain cancer drugs, highlighting a case where a drug's MRP is Rs 27,000 but sold at Rs 2,700. Meanwhile, Novartis and Eli Lilly have opposed a Kerala High Court petition seeking government price controls on two expensive breast cancer drugs, citing development and manufacturing costs. The companies' India sales represent a small fraction of their global revenues. The courts are examining drug pricing mechanisms and affordability concerns.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (40/100). Lens Score 62/100.
Outlets measured: economictimes, english. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (38–42/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
english broke this story on 26 Sept, 06:45 am. Other outlets followed.